Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy
A Research of the Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy
1 other identifier
observational
1,000
1 country
1
Brief Summary
The purpose of this study is to
- 1.Early identify patients based on clinical manifestation, imaging, gene and histology, explore diagnostic tools
- 2.get gene repertoire of Chinese
- 3.Build a cerebral amyloid angiopathy (CAA) prospective cohorts, observing the disease history, and exploring prognostic factors of hemorrhage in CAA patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2015
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
February 3, 2015
CompletedFirst Posted
Study publicly available on registry
February 11, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedFebruary 11, 2015
February 1, 2015
1.1 years
February 3, 2015
February 6, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
apolipoprotein E gene polymorphism
baseline
Secondary Outcomes (3)
CMBs were evaluated using the Microbleed Anatomical Rating Scale (MARS)
baseline
a composite outcome including multiple dot and blot hemorrhages and microaneurysms of the fundus
baseline
recurrence of cerebral hemorrhage
1 year
Eligibility Criteria
We recruited consecutive patients with intracerebral hemorrhage.
You may qualify if:
- ①diagnosed wiht spontaneous cerebral hemorrhage after the head CT.
- ② the patients and their family members agreed to participate in this study.
You may not qualify if:
- ①cerebral hemorrhage caused by traumatic, cerebral infarction, tumor and arteriovenous malformation.
- ②patients who can not provide reliable information or are considered unsuitable for the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking University Third Hospital
Beijing, 100191, China
Biospecimen
blood brain tissure
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dongsheng Fan, doctor
Peking University Third Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chairman of the department of neurolog of Peking University Third Hospital
Study Record Dates
First Submitted
February 3, 2015
First Posted
February 11, 2015
Study Start
February 1, 2015
Primary Completion
March 1, 2016
Study Completion
March 1, 2017
Last Updated
February 11, 2015
Record last verified: 2015-02